Search results
Feb 28, 2024 · Amgen is committed to advancing a bold ambition: to halve the number of heart attacks and strokes by 2030. To change the cardiovascular treatment landscape, it starts with addressing LDL-C.
- 5 Things Amgen is Doing to Help Bend the Curve in Cardiovascular ...
Amgen has maintained an ongoing commitment to helping people...
- Products | Amgen
Amgen’s medicines treat serious illnesses and typically...
- 5 Things Amgen is Doing to Help Bend the Curve in Cardiovascular ...
Apr 7, 2022 · Amgen has maintained an ongoing commitment to helping people with cardiovascular disease. It takes coordinated efforts in patient education, healthcare access and public health, along with continued biomedical innovation, to address unmet needs in preventing subsequent cardiovascular events and treating cardiovascular disease.
Amgen’s medicines treat serious illnesses and typically address diseases with a limited number of treatment options. With a presence in approximately 100 countries, we are proud to have reached millions of people with our products.
Through its own research and development efforts, as well as partnerships, Amgen is building a robust cardiovascular portfolio consisting of several approved and investigational molecules in an effort to address a number of today's important unmet patient needs, such as high cholesterol and heart failure. About Amgen
Repatha can help prevent heart attack, stroke, and certain heart procedures to restore blood flow to the heart due to a build-up of fatty deposits in your arteries (also known as atherosclerotic cardiovascular disease).
Amgen Announces Top-Line Results of Trial to Reduce Cardiovascular Events With Aranesp (R) Therapy (TREAT) in CKD Patients With Type-2 Diabetes. 08.25.2009 |. PDF Version. No Statistically Significant Difference in Cardiovascular and Renal Composite Endpoints Between Aranesp and Placebo.
Jun 1, 2022 · Amgen's olpasiran has been found to reduce levels of lipoprotein, or Lp(a), which is a risk factor for cardiovascular disease.
